NHS Prescribing of Mounjaro: the Facts Behind the Headlines

The myth: if NICE approved it, your GP can prescribe it now

This is the most common misunderstanding patients bring to a consultation. NICE published its recommendation for tirzepatide (TA1026) in December 2024, and that is genuinely significant, it means NHS England is obligated to fund access. But NICE approval and immediate GP availability are not the same thing. The rollout follows a phased commissioning timetable that NHS England sets separately, and those phases tie eligibility to specific combinations of BMI and co-existing health conditions.

From June 2025 the first group became eligible: adults with a BMI of 40 or above and at least four of five named conditions (type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea, or established cardiovascular disease). The second cohort, covering BMI 35–39.9 with the same four-condition requirement, opened in June 2026. Further phases, loosening those criteria, are planned for around March 2027 and beyond. Ethnic-background adjustments of 2.5 kg/m² apply throughout, so some South Asian, Chinese, Middle Eastern, Black African and African-Caribbean patients qualify at a lower BMI. Even within a qualifying group, meeting the numbers doesn't guarantee a prescription, the prescriber assesses each person individually, and NHS patients are expected to engage with a supervised diet and activity programme. Whether the NHS will prescribe Mounjaro in your specific situation depends on which phase is live at the time you ask.

The practical upshot: a large number of people who are clinically suitable for tirzepatide, and whose doctors agree it would help them, currently sit outside every active NHS cohort.

GP prescribing: possible from April 2026, but not universal

Before April 2026, NHS tirzepatide was restricted to specialist weight management services, which in most areas meant long referral queues. From 1 April 2026, a new GP contract (QOF 2026/27) allowed GP practices in England to prescribe tirzepatide directly, a genuine step forward. The catch is that participation is voluntary. Not every practice has signed up, and in areas where the local integrated care board hasn't prioritised rollout, patients may still find their GP is unable to prescribe it, even if they meet the criteria on paper.

Scotland, Wales and Northern Ireland operate under different frameworks. Thresholds and access routes vary by nation, so the picture that applies in England doesn't map cleanly onto the rest of the UK. If you're in Scotland, the question of whether the NHS can prescribe Mounjaro involves checking Scottish Medicines Consortium guidance as well. For anyone wanting to understand how their GP fits into this (and what to ask at their next appointment) the guide to GP prescribing of Mounjaro covers the process in plain terms.

One practical note: if your GP practice is participating, you'll need to book an appointment during their normal hours. That's straightforward for many people, but for those juggling school pickups and full-time work, even getting that appointment can take weeks.

What NHS prescribing requires from you, not just the criteria

Qualifying on paper is the start, not the finish. NICE TA1026 is explicit that tirzepatide on the NHS must be accompanied by wrap-around support: dietary advice, increased physical activity, and behavioural support as part of a structured programme. If a patient loses less than five percent of their body weight after six months at the highest dose they can tolerate, continuing treatment is subject to review. This isn't a bureaucratic hurdle for its own sake, the evidence base for tirzepatide consistently shows better outcomes when lifestyle changes run alongside treatment, and the commissioning structure reflects that.

For context on what the evidence shows about weight loss, NHS England's guidance on weight management injections explains both the expected benefits and the conditions of NHS access clearly. It's worth reading before any appointment, whether NHS or private.

Private prescribing as an alternative route

For people who don't qualify under the current NHS phases, or who would rather not wait, a private prescription is a legal and regulated option. Mounjaro remains a prescription-only medicine through any route, so a full clinical assessment is still required, no online pharmacy can legally supply it without one. The difference is that private prescribing isn't bound by the NHS cohort timetable. A GPhC-registered independent prescriber applies the licensed eligibility criteria (broadly, adults with a BMI of 30 or above, or 27-plus with a qualifying weight-related condition) rather than the narrower NHS thresholds.

For a clearer sense of what private prescribing actually involves (how the consultation works, what verification is required, and what the treatment journey looks like) getting Mounjaro prescribed is the place to start. Pricing context for private treatment is set out on the Mounjaro private prescription page, where you'll find an honest breakdown of what a single transparent price covers.

If private treatment sounds right for your situation, our prescribers carry out same-day clinical reviews, seven days a week. Speak to our prescribers through a free consultation at our weight-loss treatments page, there's no obligation, and the consultation itself costs nothing.